Shu YQ - Search Results

1

Association of ERCC1-C118T and -C8092A polymorphisms with lung cancer risk and survival of advanced-stage non-small cell lung cancer patients receiving platinum-based chemotherapy: a pooled analysis based on 39 reports.

Xu TP, Shen H, Liu LX, Shu YQ. Xu TP, et al. Among authors: shu yq. Gene. 2013 Sep 10;526(2):265-74. doi: 10.1016/j.gene.2013.05.021. Epub 2013 May 30. Gene. 2013. PMID: 23727606

2

Genomic alterations in lung adenocarcinomas detected by multicolor fluorescence in situ hybridization and comparative genomic hybridization.

Shen H, Zhu Y, Wu YJ, Qiu HR, Shu YQ. Shen H, et al. Among authors: shu yq. Cancer Genet Cytogenet. 2008 Mar;181(2):100-7. doi: 10.1016/j.cancergencyto.2007.11.012. Cancer Genet Cytogenet. 2008. PMID: 18295661

3

Multicolor fluorescence in situ hybridization and comparative genomic hybridization reveal molecular events in lung adenocarcinomas and squamous cell lung carcinomas.

Shen H, Gao W, Wu YJ, Qiu HR, Shu YQ. Shen H, et al. Among authors: shu yq. Biomed Pharmacother. 2009 Jul;63(6):396-403. doi: 10.1016/j.biopha.2008.08.010. Epub 2008 Sep 16. Biomed Pharmacother. 2009. PMID: 18848758

4

A functional genetic variant in microRNA-196a2 is associated with increased susceptibility of lung cancer in Chinese.

Tian T, Shu Y, Chen J, Hu Z, Xu L, Jin G, Liang J, Liu P, Zhou X, Miao R, Ma H, Chen Y, Shen H. Tian T, et al. Cancer Epidemiol Biomarkers Prev. 2009 Apr;18(4):1183-7. doi: 10.1158/1055-9965.EPI-08-0814. Epub 2009 Mar 17. Cancer Epidemiol Biomarkers Prev. 2009. PMID: 19293314

5

Common genetic variants on 5p15.33 contribute to risk of lung adenocarcinoma in a Chinese population.

Jin G, Xu L, Shu Y, Tian T, Liang J, Xu Y, Wang F, Chen J, Dai J, Hu Z, Shen H. Jin G, et al. Carcinogenesis. 2009 Jun;30(6):987-90. doi: 10.1093/carcin/bgp090. Epub 2009 Apr 15. Carcinogenesis. 2009. PMID: 19369581

6

CD13+CD4+CD25hi regulatory T cells exhibit higher suppressive function and increase with tumor stage in non-small cell lung cancer patients.

Ju S, Qiu H, Zhou X, Zhu B, Lv X, Huang X, Li J, Zhang Y, Liu L, Ge Y, Johnson DE, Ju S, Shu Y. Ju S, et al. Cell Cycle. 2009 Aug 15;8(16):2578-85. doi: 10.4161/cc.8.16.9302. Epub 2009 Aug 19. Cell Cycle. 2009. PMID: 19597336

7

Involvement of mTOR and survivin inhibition in tamoxifen-induced apoptosis in human hepatoblastoma cell line HepG2.

Guo R, Wang T, Shen H, Ge HM, Sun J, Huang ZH, Shu YQ. Guo R, et al. Among authors: shu yq. Biomed Pharmacother. 2010 Apr;64(4):249-53. doi: 10.1016/j.biopha.2009.06.007. Epub 2009 Oct 22. Biomed Pharmacother. 2010. PMID: 19931998

8

The effect of endostatin and gemcitabine combined with HIFU on the animal xenograft model of human pancreatic cancer.

Wang RS, Liu LX, Gu YH, Lin QF, Guo RH, Shu YQ. Wang RS, et al. Among authors: shu yq. Biomed Pharmacother. 2010 May;64(5):309-12. doi: 10.1016/j.biopha.2009.09.011. Epub 2009 Nov 5. Biomed Pharmacother. 2010. PMID: 19942398

9

Combined tamoxifen and gefitinib in non-small cell lung cancer shows antiproliferative effects.

Shen H, Yuan Y, Sun J, Gao W, Shu YQ. Shen H, et al. Among authors: shu yq. Biomed Pharmacother. 2010 Feb;64(2):88-92. doi: 10.1016/j.biopha.2009.06.010. Epub 2009 Oct 23. Biomed Pharmacother. 2010. PMID: 20005069

10

A 3'-untranslated region polymorphism in IGF1 predicts survival of non-small cell lung cancer in a Chinese population.

Zhang M, Hu Z, Huang J, Shu Y, Dai J, Jin G, Tang R, Dong J, Chen Y, Xu L, Huang X, Shen H. Zhang M, et al. Clin Cancer Res. 2010 Feb 15;16(4):1236-44. doi: 10.1158/1078-0432.CCR-09-2719. Epub 2010 Feb 9. Clin Cancer Res. 2010. PMID: 20145156

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

465 results

Search Page

Filters